ZNTL - Zentalis Pharmaceuticals Llc logo

ZNTL

Zentalis Pharmaceuticals Llc

Rev —top 1%5Y
Hold

Zentalis Pharmaceuticals develops small molecule therapeutics for cancer treatment, focusing on azenosertib in clinical trials for ovarian and other solid tumors. The company targets therapies for patients resistant to existing treatments.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $85today

Score Overview

1 Year
Score
Net Growth9.43%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth21.79%
Net Trend60%
Net Income Consistency
Rev Growth
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-5.34%
Net Trend50%
Net Income Consistency
Rev Growth
Rev Trend17%
Revenue Consistency

See the full market ranking →

Zentalis Pharmaceuticals Llc fundamental performance

Across Zentalis Pharmaceuticals Llc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 117M to -$ 137M. Revenue increased in 17% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.29
1 Year2025-08-12
$ 1.41204.26%
5 Years2021-08-12
$ 50.19-91.45%
All Time2020-04-03
$ 23.20-81.51%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 124M$ 211M
2025$ 0.00-$ 137M$ 245M
2024$ 67M-$ 165M$ 371M
2023$ 0.00-$ 292M$ 482M
2022$ 0.00-$ 236M$ 437M
2021$ 0.00-$ 158M$ 340M
IPO2020$ 0.00-$ 117M$ 338M

Explore beyond ZNTL

You're looking at Zentalis Pharmaceuticals Llc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies